Molecular docking analysis revealed significant interactions between the androgen receptor (PDB ID: 1r4i), a key target in prostate cancer, and three ligands: Atractylenolide II, Atractylenolide III, and Enzalutamide (ENZ). This evidence concerns the gene AR and prostate carcinoma.